Free Case Review for NAION Claims

This page connects NAION-focused visitors to the site’s direct case-review path and next-step guidance.

GLP-1 receptor agonists, NAION vision-loss questions, and semaglutide safety updates
EMA PRAC (June 6, 2025): recommended listing NAION as a very rare side effect (up to 1 in 10,000) for semaglutide medicines
MDL No. 3163 centralized in the Eastern District of Pennsylvania on Dec 15, 2025; JPML report dated Apr 1, 2026 lists 73 pending actions

Medical research

Public studies continue to assess GLP-1 and NAION risk signals

Retrospective studies in 2024 and 2025 raised NAION risk questions in semaglutide users, but findings remain mixed. Read this as evolving medical context before drawing individual conclusions.

Safety updates

EMA PRAC recommended a very-rare NAION label update for semaglutide

On June 6, 2025, EMA PRAC recommended listing NAION as a very rare side effect for Ozempic, Rybelsus, and Wegovy. Safety labels can continue changing as evidence updates.

Public litigation

MDL 3163 remains active in federal court tracking

JPML centralized these federal GLP-1 and NAION cases in the Eastern District of Pennsylvania on Dec 15, 2025. The Apr 1, 2026 pending report lists 73 pending actions.

Related pages

Continue with these pages

These related pages help visitors continue reading and compare nearby topics without losing the main page context.

What Is NAION?

This page explains what NAION is, why sudden vision-loss symptoms matter, and which public background points visitors usually review first.

Visit page

GLP-1 Drugs and NAION

Review how GLP-1 receptor agonists such as Ozempic, Wegovy, and related medicines appear in public NAION discussions, studies, and safety updates.

Visit page

NAION Symptoms and Diagnosis

This page outlines common NAION-related symptom descriptions and diagnosis context so visitors can compare public information with their own timeline.

Visit page

Who May Qualify

Use this page for an initial relevance check based on medication history, symptom timing, and medical context before deciding on the next…

Visit page

Lawsuit Updates

This page tracks NAION-related lawsuit updates, including MDL 3163 context, court developments, and connected source summaries.

Visit page

NAION Free Case Review path

This page keeps the NAION section connected to the site’s direct case-review path and contact options.

Move into Free Case Review.
Keep the next step calm and clear.
Return to NAION Claims or About pages when needed.